# Swift Resolution of a Peristomal Skin Complication Utilising a Ceramide Infused Barrier



### Case Study

### Abstract:

People with ostomies can face a variety of challenges. Many of these challenges might be avoided with the correct initial product selection that is based more on evidence than on experience. This case explores the set of challenges a patient experienced that appeared mainly due to using ostomy products lacking both fit and formulation properties to manage his stoma.

### **Relevant Medical History:**

Mr. B (initial changed to protect privacy) is a sixty-one-year-old male originally from Samoa. In 2004, he was diagnosed with a gastrointestinal stromal tumour (GIST) and underwent his first surgical procedure for removal of the tumour and formation of a temporary ileostomy. GISTs are soft tissue sarcomas that may be found any part of the digestive system but most frequently in stomach and small intestine.<sup>1</sup> Most GISTs remain 'silent' until reaching a large size and symptoms can vary according to location and size.<sup>2</sup> In the case of Mr. B, his tumour was assumed to be in the small intestine. GISTs can develop in people of all ages, but most commonly between age 50 and 70, and almost never occurring before age 40.<sup>1,2</sup>

Later, his ileostomy was reversed, however the GIST spread to his rectum, and in 2007 after refusing an abdomino-perineal resection (APR) he required further surgical excision with another temporary ileostomy formed that was also reversed at a later date. Metastatic spread occurs often and usually 10-15 years after original surgery.<sup>2</sup> However, his symptoms worsened at a faster pace, and he underwent an APR with vertical rectus abdominis myocutaneous flap (VRAM) in 2012 and formation of a permanent colostomy. The VRAM flap is preferred for pelvic reconstruction as it is a combination myocutaneous flap comprised of three layers: skin, subcutaneous fat, and muscle. This triple-layer anatomy makes the VRAM flap durable, and the flap can be used to cover skin defects.<sup>3</sup>

### **Background:**

Originally, Mr. B was managed at another district health board (DHB) further south in New Zealand, so access to some of his information proved challenging. He spoke little to no English and communication was mainly through his wife. Additionally, to complicate things further, he previously had a cerebrovascular accident (CVA) in 2017 that left him with expressive dysphasia but no other residual deficits such as motor skill challenges. He was still ambulatory and independent in self-care. However, this expressive dysphasia often left him feeling frustrated, resulting in him becoming non-conversant with his wife.

He also suffered with chronic renal failure (his creatinine was 211). Of note, people of all genders and ages suffering with chronic renal failure, are also prone to pruritis (chronic itching).<sup>4</sup> He was also obese with a body mass index of 40. Generally, a healthy BMI is between 18.5 and 24.9, however this may be higher in people of Polynesian origin.<sup>5</sup>

Lastly, he had recurrence of tumour locally in the perineal region requiring treatment in Auckland at our hospital. This required both he and his wife move into emergency accommodation near our hospital.

#### **Skin Profile:**

At initial review, his skin had multiple broken areas that appeared visually reddened and inflamed fully circumferential to the stoma. The affected skin was only directly under the barrier footprint and did not extend beyond the skin barrier edges. This type of skin reaction was determined to be a Peristomal Medical Adhesive Related Skin Injury (PMARSI) as he was not

continued on back



Figure 1 CeraPlus one-piece pouching system with flat cut-to-fit skin barrier.




Figure 2 Ceramides help with TEWL by holding cells together, retaining moisture, and replenishing the skins' natural barrier.



**Figure 3** Peristomal skin condition appears visually improved after 3 days.

# Swift Resolution of a Peristomal Skin Complication Utilising a Ceramide Infused Barrier

Emma Ludlow RN STN Middlemore Hospital Counties Manukau District Health Board New Zealand

## Case Study

experiencing leakages. PMARSI differs from irritant contact dermatitis where skin is exposed to stoma effluent. Here, the issue is related rather to the exposure of skin to an adhesive.<sup>6</sup>

His wife reported that he had been tried three different brands of ostomy products with poor success. She said he expressed that his skin was very itchy and painful. As described, his history was vague on some of the aspects of his care, but it appeared they may have also tried cortico-steroid creams, and other topical agents such as wipes without success. His wife reported that he could guess when his stoma would be active and would often leave the pouching system off and his skin exposed to air to gain relief.

### **Products Used and Outcomes:**

A skin barrier infused with ceramide (CeraPlus skin barrier with Remois Technology<sup>\*</sup>) was chosen. (See Figure 1). Ceramides are naturally occurring waxy lipids that occur naturally in human skin that help reduce trans-epidermal water loss (TEWL) which is water loss through the stratum corneum.<sup>7</sup> (See Figure 2) .When peristomal skin is healthy, skin keeps moisture in and irritants out. The product type chosen was a flat, cut-to-fit one-piece closed pouching system. While Mr. B had no dexterity issues, his wife would cut the barriers to the desired template size and shape as instructed. The output from his stoma was regular and thusly, he only needed to change the pouching system once per day. Within only three days, his skin appeared markedly improved visually. (See Figure 3). It was unfortunate a 'before' image was not captured to clearly demonstrate how severely compromised his skin had been. No accessories or other materials were required.

Mr. B (via his wife) expressed how happy they were with the results. He reported a quick resolution in his itching and discomfort, and she commented how much healthier his peristomal skin appeared visually. They are reporting that his skin continues to improve.

### **Conclusion:**

Clearly, not all skin barrier adhesives are the same. Products are often chosen based on style when the more important consideration is the critical goal of proactively attaining and maintaining healthy peristomal skin. Without healthy peristomal skin, other product features become irrelevant. This was his fourth pouching system evaluated and the only one to provide Mr. B with rapid resolution of his skin condition and itching. CeraPlus skin barriers through their fit and formulation attributes, may help assist patients in the prevention of peristomal skin complications such as PMARSI and TEWL from occurring.

CE

#### References

- Mayo Clinic 2020, 'Gastrointestinal stromal tumor (GIST)', https://www.mayoclinic.org/diseases-conditions/gastrointestinal-stromaltumors/cdc-20387715, Accessed March 2020.
- 2. Xiaohui, Z & Changjun, Y 2012, 'Gastrointestinal stromal tumor', Journal of Gastrointestinal Oncology, vol. 3, no. 3, pp. 189–208.
- Sagebiel, TL, Faria, SC, Balachandran, A, Sacks, JM, You, YN & Bhosale, PR 2011, 'Pelvic reconstruction with omental and VRAM flaps: Anatomy, surgical technique, normal postoperative findings, and complications', *RadioGraphics*, vol. 31, no. 7.
- 4. Vyas, R 2010, 'Uraemic pruritus', DermNet NZ, https://dermnetnz.org/topics/uraemic-pruritus/, Accessed March 2020.
- Australian Government, Department of Health, 'Body Mass Index', http://healthyweight.health.gov.au/wps/portal/Home/getstarted/are-you-a-healthy-weight/bmi, Accessed March 2020.
- Kimberly, LeBlanc, K, Whiteley, I, McNichol, L, Salvadalena, G & Gray, M 2019, 'Peristomal Medical Adhesive-Related Skin Injury -Results of an international consensus meeting', Journal of Wound Ostomy & Continence Nursing, vol. 46, no. 2, pp. 125-136.
- Grove G, Houser T, Sibbald, G & Salvadalena, G 2019, 'Measuring epidermal effects of ostomy skin barriers', Journal of Skin Research Technology, vol. 25, no. 2, pp: 179-186.



\*Remois is a technology of Alcare Co., Ltd.

Prior to use, be sure to read the Instructions for Use for information regarding Intended Use, Contraindications, Warnings, Precautions, and Instructions.

The Hollister logo and CeraPlus are trademarks of Hollister Incorporated. All other trademarks and copyrights are the property of their respective owners. Not all products are CE marked. © 2020 Hollister Incorporated. AUH245. April 2020.



Australia Suite 3, Ground floor 990 Whitehorse Rd Box Hill VIC 3128 1800 880 840 New Zealand

58 Richard Pearse Drive, Airport Oaks, Auckland, New Zealand 0800 678 669

www.hollister.com.au

www.hollister.co.nz